Vericel Overview
Valuation check: VCEL's ROE is 6.55%, below the Healthcare sector average of 11.15%.
Get informed when a big investor buys or sells
+ Follow6.55%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Vericel (VCEL) currently reports a ROE of 6.55%. That is below the Healthcare sector average of 11.15%. Use the charts on this page to explore Vericel's ROE history and peer comparisons.
Vericel's ROE of 6.55% is lower than the Healthcare sector average of 11.15%. That is roughly 41.3% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Vericel's current 6.55% should be judged against Healthcare norms (sector average: 11.15%) and against VCEL's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 6.55%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Vericel, and consider following VCEL for alerts when major investors trade the stock.
Vericel is classified in the Healthcare sector. On ROE, it currently shows 6.55% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VCEL with unrelated industries.
